IL1B and chronic obstructive pulmonary disease: These data imply that the inflammasome is not triggered in these clinical conditions, probably explaining the discrepancy in literature and the unsuccessful randomized clinical trials performed on stable COPD patients subjected to canakinumab (monoclonal antibody against IL-1β) or an anti-P2X7 antagonist (1).